Xinsu Technology

Xinsu Technology (芯宿科技) is a Chinese startup applying semiconductor techniques to biology — its stated vision is to build "molecular chips" for high-throughput synthesis and detection of DNA, RNA, and proteins, with the goal of driving the cost of synthesizing biomacromolecules down by orders of magnitude and serving synthetic biology, biopharma, and DNA data storage applications . It was founded by Zhao Xin — a FreeS Fund piece dates the founding to 2020 , while a later funding announcement describes the company as established in 2021, setting up in Suzhou Industrial Park in Q4 of that year . It positions itself as the first domestic company developing molecular-chip-based DNA synthesis, and by mid-2022 had completed proof-of-concept plus a desktop high-throughput DNA synthesizer prototype, and was already serving biotech firms and research institutes with primer synthesis, gene synthesis, subcloning, and related services .

FreeS Fund has backed it from the start, leading its tens-of-millions angel round in 2021 and framing it as a bet on "the semiconductorization of biotech" ; a tens-of-millions angel+ round followed in mid-2022, led by Qiming Venture Partners with FreeS and Xinhang Capital participating , and by 2023 it had raised a nine-figure Pre-A round . Within FreeS's portfolio it sits in the synthetic-biology enabling-tools bucket, alongside names like Bluepha and GenScript-adjacent plays . Note the most recent coverage in this corpus is from 2023, so later developments aren't reflected here.